Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company pioneering viral immunotherapies for solid tumor treatment. This page serves as the definitive source for official updates on the company's innovative adenovirus and herpes simplex virus (HSV) platform developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing therapy advancements, peer-reviewed research collaborations, and manufacturing updates relevant to CADL's immuno-oncology pipeline.
Key content categories include phase trial results, FDA communications, intellectual property developments, and executive leadership announcements. All materials are sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page for streamlined access to Candel Therapeutics' latest developments in cancer immunotherapy. Check regularly for updates on their gmci™ and rqnestin34.5 platforms as they progress through clinical evaluation.
Candel Therapeutics announced on April 17, 2023, that the FDA has granted fast track designation for its investigational viral immunotherapy CAN-2409 combined with valacyclovir and pembrolizumab. This designation aims to expedite the drug's development for patients with late-stage non-small cell lung cancer (NSCLC) resistant to first-line therapies. CAN-2409 targets patients without molecular driver mutations and aims to enhance survival rates and delay disease progression. Clinical trial data revealed a 77% disease control rate in a subset of patients with previous treatment failures. The company plans to present updated data from the ongoing Phase 2 trial in the third quarter of 2023, showcasing the potential of CAN-2409 in treating various solid tumors.
Candel Therapeutics, Inc. (Nasdaq: CADL) reported financial results for Q4 and FY 2022, showcasing promising advancements in its viral immunotherapy programs. The company extended its cash runway into Q2 2024 with cash and equivalents of $70.1 million, down from $82.6 million in 2021. Notably, CAN-2409 demonstrated a 77% disease control rate in non-small cell lung cancer patients. Candel anticipates multiple clinical data readouts in 2023, including topline results from its prostate cancer trial in Q4 2024. Despite a net loss of $5.1 million for Q4 2022, the company's strategic partnerships and ongoing trials bolster its potential to innovate cancer treatments.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
